Registration Dossier

Diss Factsheets

Administrative data

Description of key information

The acute toxicity of CaDDBS via oral exposures was tested in rats.  The acute dermal toxicity of the analogue NaLAS was also tested in rats. No acute toxicity was observed at doses exceeding the maximum limit doses for both the oral or dermal exposures. Therefore, CaDDBS is not classified either under the DSD or the CLP.

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Dose descriptor:
LD50
Value:
4 445 mg/kg bw

Acute toxicity: via dermal route

Endpoint conclusion
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Additional information

Groups of 10 female rats were exposed by oral gavage to doses of 2500, 3200, 5000, and 6300 mg/kg of calcium dodecylbenzene sulphonate. The animals were then monitored for the 14 days for mortality, and weighed weekly. The LD50 was determined to be 4445 mg/kg. Surviving animals showed no effects. Dermal toxicity was examined for the sodium salt of LAS. The clipped skin on the backs of five male and five female rats were exposed to LAS under an occlusive dressing for 24 hours and observed for another 14 days. Results indicate slight erythema and slight oedema but no acute mortality. The dermal LD50 is > 2000 mg/kg. Based on these results it is concluded that calcium dodecylbenzene sulphonate is not acute toxic via either oral or dermal exposures at doses exceeding the limit doses.

Justification for classification or non-classification

No acute toxicity was observed at doses exceeding the limit doses for oral or dermal exposures. Therefore, CaDDBS is not classified either under the DSD or the CLP.

Categories Display